ConductScience.org, home

Paper65560

Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Birkmayer W and 3 others. Lancet, 1977. Cited by 269 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Papers, record 65560. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/65560

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.
PubMed
Journal
Lancet
PubMed
Year
1977
PubMed
Publication types
Clinical Trial, Comparative Study, Journal Article
PubMed
Citations, by iCite
269
iCite
Relative citation ratio, by iCite
8.55
iCite
Revised in PubMed
2022-03-11
PubMed

Authors4

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Birkmayer WW
2Riederer PP
3Ambrozi LL
4Youdim MBM B

Source PubMed

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
BenserazideMajor topic
HydrazinesMajor topic
LevodopaMajor topic
Monoamine Oxidase InhibitorsMajor topic
Parkinson DiseaseMajor topic
PhenethylaminesMajor topic
Administration, Oral
Aged
Clinical Trials as Topic
Disability Evaluation
Drug Combinations
Drug Evaluation
Drug Synergism
Drug Therapy, Combination
Female
Follow-Up Studies
Humans
Injections, Intravenous
Male
Time Factors

Source PubMed

Cited by67

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 269 citations.

PMIDTitleJournalYearIn PapersSource
42,199,369Heterologous expression of hydroxylase coupled with pathway optimization enables highly efficient ʟ-DOPA production in Corynebacterium glutamicum.Synth Syst Biotechnol2026https://conductscience.org/library/papers/42199369PubMed
41,972,109Amantadine-based combination therapy of Parkinson's disease to prevent fluctuation and dyskinesia - experiences from a Parkinson outpatient clinic.Front Aging Neurosci2026https://conductscience.org/library/papers/41972109PubMed
40,650,193Parkinson Disease Signaling Pathways, Molecular Mechanisms, and Potential Therapeutic Strategies: A Comprehensive Review.Int J Mol Sci2025https://conductscience.org/library/papers/40650193PubMed
37,796,288L-DOPA-therapy in Parkinson's disease: some personal reflections on L-DOPA therapy from Vienna and Berlin.J Neural Transm (Vienna)2023https://conductscience.org/library/papers/37796288PubMed
37,686,140Striking Neurochemical and Behavioral Differences in the Mode of Action of Selegiline and Rasagiline.Int J Mol Sci2023https://conductscience.org/library/papers/37686140PubMed
36,810,524Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions.Signal Transduct Target Ther2023https://conductscience.org/library/papers/36810524PubMed
35,622,265Garcinia morella extract confers dopaminergic neuroprotection by mitigating mitochondrial dysfunctions and inflammation in mouse model of Parkinson's disease.Metab Brain Dis2022https://conductscience.org/library/papers/35622265PubMed
35,394,205Treatment; Moussa B.H. Youdim.J Neural Transm (Vienna)2022https://conductscience.org/library/papers/35394205PubMed
35,110,492Recent Advances in Drug Therapy for Parkinson's Disease.Intern Med2023https://conductscience.org/library/papers/35110492PubMed
34,977,548Rasagiline does not exacerbate autonomic blood pressure dysregulation in early or mild Parkinson's disease.Clin Park Relat Disord2022https://conductscience.org/library/papers/34977548PubMed
31,974,721The discovery and development of rasagiline as a new anti-Parkinson medication.J Neural Transm (Vienna)2020https://conductscience.org/library/papers/31974721PubMed
31,562,557Selegiline: a molecule with innovative potential.J Neural Transm (Vienna)2020https://conductscience.org/library/papers/31562557PubMed
30,341,696Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases.J Neural Transm (Vienna)2018https://conductscience.org/library/papers/30341696PubMed
29,417,334Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson's disease.J Neural Transm (Vienna)2018https://conductscience.org/library/papers/29417334PubMed
29,387,272Effects on Sperms' Quality of Selegiline in Aged Rats.Open Med Chem J2017https://conductscience.org/library/papers/29387272PubMed
28,515,684Selegiline Ameliorates Depression-Like Behavior in Mice Lacking the CD157/BST1 Gene, a Risk Factor for Parkinson's Disease.Front Behav Neurosci2017https://conductscience.org/library/papers/28515684PubMed
27,763,504Neuroprotective Effect of the Marine-Derived Compound 11-Dehydrosinulariolide through DJ-1-Related Pathway in In Vitro and In Vivo Models of Parkinson's Disease.Mar Drugs2016https://conductscience.org/library/papers/27763504PubMed
27,480,491The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).Mol Psychiatry2016https://conductscience.org/library/papers/27480491PubMed
27,252,617Multi-Target Directed Donepezil-Like Ligands for Alzheimer's Disease.Front Neurosci2016https://conductscience.org/library/papers/27252617PubMed
27,145,762Nrf2: a modulator of Parkinson's disease?J Neural Transm (Vienna)2016https://conductscience.org/library/papers/27145762PubMed

See all 67 cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/65560

GET https://conductscience.org/api/papers/v1/65560/cited_by?page=2